scriptaid has been researched along with Endometrial Neoplasms in 2 studies
scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the early-stage endometrial cancer can be effectively managed with surgery, more advanced stages of the disease require multimodality treatment with varying results." | 2.58 | Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy? ( Alavanos, A; Andreatos, N; Angelou, A; Antoniou, EA; Apostolou, KG; Athanasiou, A; Damaskos, C; Damaskou, Z; Daskalopoulou, A; Diamantis, E; Dimitroulis, D; Garmpi, A; Garmpis, N; Kalampokas, E; Kalampokas, T; Kontzoglou, K; Kostakis, A; Lavaris, A; Mantas, D; Margonis, GA; Markatos, K; Moschos, MM; Nikiteas, N; Nonni, A; Perrea, D; Sampani, A; Schizas, D; Spartalis, E; Spartalis, M; Tsivelekas, K; Tsourouflis, G; Valsami, S, 2018) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of Scriptaid, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | 1.33 | A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garmpis, N | 1 |
| Damaskos, C | 1 |
| Garmpi, A | 1 |
| Spartalis, E | 1 |
| Kalampokas, E | 1 |
| Kalampokas, T | 1 |
| Margonis, GA | 1 |
| Schizas, D | 1 |
| Andreatos, N | 1 |
| Angelou, A | 1 |
| Lavaris, A | 1 |
| Athanasiou, A | 1 |
| Apostolou, KG | 1 |
| Spartalis, M | 1 |
| Damaskou, Z | 1 |
| Daskalopoulou, A | 1 |
| Diamantis, E | 1 |
| Tsivelekas, K | 1 |
| Alavanos, A | 1 |
| Valsami, S | 1 |
| Moschos, MM | 1 |
| Sampani, A | 1 |
| Nonni, A | 1 |
| Antoniou, EA | 1 |
| Mantas, D | 1 |
| Tsourouflis, G | 1 |
| Markatos, K | 1 |
| Kontzoglou, K | 1 |
| Perrea, D | 1 |
| Nikiteas, N | 1 |
| Kostakis, A | 1 |
| Dimitroulis, D | 1 |
| Takai, N | 1 |
| Ueda, T | 1 |
| Nishida, M | 1 |
| Nasu, K | 1 |
| Narahara, H | 1 |
1 review available for scriptaid and Endometrial Neoplasms
| Article | Year |
|---|---|
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Topics: Antineoplastic Agents; Endometrial Neoplasms; Endometrium; Female; Histone Deacetylase Inhibitors; H | 2018 |
1 other study available for scriptaid and Endometrial Neoplasms
| Article | Year |
|---|---|
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Topics: Annexin A5; Apoptosis; Cell Cycle; Cell Line, Tumor; Endometrial Neoplasms; Enzyme Inhibitors; Epith | 2006 |